• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用表达疟原虫蛋白的乳酸乳球菌经口和鼻内免疫小鼠后,其年龄依赖性全身抗体反应及免疫相关变化

Age-dependent systemic antibody responses and immunisation-associated changes in mice orally and nasally immunised with Lactococcus lactis expressing a malaria parasite protein.

作者信息

Moorthy S A V, Yasawardena S G, Ramasamy R

机构信息

National Science Foundation, Sri Lanka.

出版信息

Vaccine. 2009 Aug 6;27(36):4947-52. doi: 10.1016/j.vaccine.2009.06.011. Epub 2009 Jun 21.

DOI:10.1016/j.vaccine.2009.06.011
PMID:19545652
Abstract

Gram positive food-grade bacteria such as lactococci have significant advantages over attenuated pathogens as vaccine delivery vehicles because of their inherently greater safety. Plasmodium falciparum merozoite surface antigen 2 (MSA2) was expressed in recombinant Lactococcus lactis both intracellularly and covalently anchored to the peptidoglycan of the cell wall (MSA2cP). Balb/c mice of different ages were immunised with the MSA2cP expressing L. lactis in a combined oral and nasal immunisation procedure. Serum IgG antibody responses to MSA2 were higher in young adult Balb/c mice compared to old mice and neonates. The elicited serum IgG antibodies reacted with native MSA2 on the surface of P. falciparum merozoites in an immunofluorescence assay. The serum IgG antibody isotypes in young adult mice were mainly IgG1, IgG2a and IgG2b, while IgG3 tended to be higher in old mice. IgA antibodies to MSA2 were also produced in young mice. Enlarged mesenteric lymph nodes, and more prominent lymphoid tissue in the lamina propria of the ileum and lymphoid follicles in the spleen, were observed in mice fed L. lactis. These findings are relevant for developing L. lactis as a vector to deliver vaccines in human populations.

摘要

革兰氏阳性食品级细菌,如乳酸球菌,作为疫苗载体,相较于减毒病原体具有显著优势,因为其本质上具有更高的安全性。恶性疟原虫裂殖子表面抗原2(MSA2)在重组乳酸乳球菌中进行了表达,既在细胞内表达,也共价锚定在细胞壁的肽聚糖上(MSA2cP)。采用口服和鼻腔联合免疫程序,用表达MSA2cP的乳酸乳球菌对不同年龄的Balb/c小鼠进行免疫。与老年小鼠和新生小鼠相比,年轻成年Balb/c小鼠对MSA2的血清IgG抗体反应更高。在免疫荧光试验中,所诱导产生的血清IgG抗体与恶性疟原虫裂殖子表面的天然MSA2发生反应。年轻成年小鼠的血清IgG抗体亚型主要为IgG1、IgG2a和IgG2b,而老年小鼠中的IgG3往往更高。年轻小鼠中也产生了针对MSA2的IgA抗体。在喂食乳酸乳球菌的小鼠中,观察到肠系膜淋巴结肿大,回肠固有层的淋巴组织和脾脏中的淋巴滤泡更为明显。这些发现对于将乳酸乳球菌开发为在人群中递送疫苗的载体具有重要意义。

相似文献

1
Age-dependent systemic antibody responses and immunisation-associated changes in mice orally and nasally immunised with Lactococcus lactis expressing a malaria parasite protein.用表达疟原虫蛋白的乳酸乳球菌经口和鼻内免疫小鼠后,其年龄依赖性全身抗体反应及免疫相关变化
Vaccine. 2009 Aug 6;27(36):4947-52. doi: 10.1016/j.vaccine.2009.06.011. Epub 2009 Jun 21.
2
Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations.乳酸乳球菌展示的疟原虫抗原在口服免疫中的免疫原性。
Vaccine. 2006 May 1;24(18):3900-8. doi: 10.1016/j.vaccine.2006.02.040. Epub 2006 Mar 2.
3
Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.一种重组疟疾候选疫苗(恶性疟原虫AMA-1胞外结构域的I+II结构域,来自印度恶性疟原虫等位基因)的免疫原性。
Vaccine. 2008 Aug 18;26(35):4526-35. doi: 10.1016/j.vaccine.2008.06.031. Epub 2008 Jun 30.
4
A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies.一种恶性疟原虫谷氨酸富蛋白-裂殖子表面蛋白3嵌合蛋白;在乳酸乳球菌中的表达、免疫原性及生物活性抗体的诱导
Vaccine. 2004 Mar 12;22(9-10):1188-98. doi: 10.1016/j.vaccine.2003.09.017.
5
Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.含恶性疟原虫裂殖子表面蛋白-1 羧基端 19 kDa 片段和鼠伤寒沙门氏菌鞭毛蛋白 FliC 天然免疫激动剂的重组融合蛋白的免疫原性。
Vaccine. 2010 Apr 1;28(16):2818-26. doi: 10.1016/j.vaccine.2010.02.004. Epub 2010 Feb 17.
6
Mucosal immunisation of mice with malaria protein on lactic acid bacterial cell walls.
Vaccine. 2007 May 4;25(18):3636-45. doi: 10.1016/j.vaccine.2007.01.070. Epub 2007 Jan 22.
7
Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines.基于恶性疟原虫顶端膜抗原1(PfAMA1)的DNA、蛋白质和重组改良安卡拉痘苗疫苗的初免-加强免疫方案在小鼠中诱导的免疫反应。
Vaccine. 2006 Sep 11;24(37-39):6187-98. doi: 10.1016/j.vaccine.2006.05.099. Epub 2006 Jun 12.
8
Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth.腺病毒载体诱导产生能够有效抑制红内期疟原虫生长的功能性抗体。
Vaccine. 2010 Apr 19;28(18):3201-10. doi: 10.1016/j.vaccine.2010.02.024. Epub 2010 Feb 25.
9
Immunogenicity of recombinant BCG-based vaccine expressing the 22 kDa of serine repeat antigen (SE22) of Plasmodium falciparum.表达恶性疟原虫22 kDa丝氨酸重复抗原(SE22)的重组卡介苗疫苗的免疫原性。
Trop Biomed. 2012 Jun;29(2):239-53.
10
Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.用一种疟疾传播阻断候选疫苗Pfs25进行鼻腔免疫,可在小鼠中诱导出针对恶性疟原虫野外分离株的完全保护性免疫。
Infect Immun. 2005 Nov;73(11):7375-80. doi: 10.1128/IAI.73.11.7375-7380.2005.

引用本文的文献

1
COVID-19 Vaccines for Optimizing Immunity in the Upper Respiratory Tract.优化上呼吸道免疫的 COVID-19 疫苗。
Viruses. 2023 Oct 31;15(11):2203. doi: 10.3390/v15112203.
2
Needle-free, spirulina-produced Plasmodium falciparum circumsporozoite vaccination provides sterile protection against pre-erythrocytic malaria in mice.无针、螺旋藻产生的恶性疟原虫环子孢子蛋白疫苗可在小鼠中提供针对红细胞前期疟疾的无菌保护。
NPJ Vaccines. 2022 Oct 4;7(1):113. doi: 10.1038/s41541-022-00534-5.
3
Innate and Adaptive Immune Responses in the Upper Respiratory Tract and the Infectivity of SARS-CoV-2.
上呼吸道的固有和适应性免疫反应与 SARS-CoV-2 的传染性。
Viruses. 2022 Apr 29;14(5):933. doi: 10.3390/v14050933.
4
Construction of Recombinant Strain Expressing VP1 Fusion Protein of Duck Hepatitis A Virus Type 1 and Evaluation of Its Immune Effect.1型鸭甲型肝炎病毒VP1融合蛋白表达重组菌株的构建及其免疫效果评价
Vaccines (Basel). 2021 Dec 14;9(12):1479. doi: 10.3390/vaccines9121479.